Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Cwm LLC

Cwm LLC increased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 128.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,298 shares of the biopharmaceutical company’s stock after acquiring an additional 5,232 shares during the period. Cwm LLC’s holdings in Catalyst Pharmaceuticals were worth $185,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Oppenheimer & Co. Inc. acquired a new position in shares of Catalyst Pharmaceuticals in the first quarter worth about $805,000. Sei Investments Co. boosted its position in shares of Catalyst Pharmaceuticals by 64.3% during the 1st quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company’s stock valued at $1,329,000 after acquiring an additional 32,621 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $954,000. Vanguard Group Inc. raised its holdings in Catalyst Pharmaceuticals by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 7,120,417 shares of the biopharmaceutical company’s stock valued at $119,694,000 after buying an additional 73,930 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Catalyst Pharmaceuticals in the second quarter valued at approximately $258,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $21.34 on Thursday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $11.89 and a 12 month high of $21.85. The firm’s fifty day simple moving average is $20.31 and its 200-day simple moving average is $17.53. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of 39.52, a PEG ratio of 3.18 and a beta of 0.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.39 by $0.13. The firm had revenue of $122.71 million during the quarter, compared to analysts’ expectations of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. Analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current year.

Insider Transactions at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the sale, the insider now directly owns 675,124 shares in the company, valued at $13,738,773.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 201,058 shares of company stock valued at $4,018,188 over the last three months. 11.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on CPRX. Citigroup increased their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial increased their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright upped their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average price target of $29.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.